Dorin Artzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dorin Artzi has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Alexei Wirganowicz
Department of Molecular Biology and Genetics, Cornell University, Ithaca, USA
2 shared publicationsElla Sultan
Meinig School of Biomedical Engineering, Cornell University, Ithaca, USA
2 shared publicationsEvelyn Goldwasser
College of Agriculture and Life Sciences, Cornell University, Ithaca, USA
2 shared publications- Guoting Qin
Mass Spectrometry Laboratory, College of Optometry, University of Houston, Houston, USA
2 shared publications Justin Lau
Meinig School of Biomedical Engineering, Cornell University, Ithaca, USA
2 shared publications- Nadine Elkasri
Meinig School of Biomedical Engineering, Cornell University, Ithaca, USA
2 shared publications
Latest Publications
- 5 November 2026
- Published by Springer Nature in Nature Nanotechnology
- p. 1-14
Repurposed endogenous virus-like vesicles mediate dendritic cell long-range antigen presentation and T cell activation for enhanced cancer vaccination
Dendritic cells release extracellular vesicles (DEVs) that amplify antigen presentation while incorporating patient-derived, rapidly evolving antigens. By enriching peptide–major histocompatibility complex (MHC) and co-stimulatory ligands orders of magnitude above donor-cell levels, DEVs emerge as potent vesicle-vaccines, although efficacy remains limited by unclear mechanisms. Here we show that dendritic cells repurpose the virus-like retrotransposon-derived Arc gene to generate endogenous virus-like vesicles (VLVs) that predominantly carry peptide–MHC and high-density co-stimulatory ligands, intensifying and extending antigen presentation. Upon antigen exposure, Arc partners with endogenous envelope proteins to assemble VLVs that directly engage T cells and trigger intrinsic adjuvanticity via viral mimicry. DEVs lacking Arc failed to prime antigen-specific T cell responses, whereas Arc overexpression shifted DEVs toward VLVs that trafficked to lymphoid organs, drove rapid CD4-assisted priming and durable CD8-biased memory, suppressed melanoma, and prolonged survival. Our data reveal a viral-mimicry mechanism enabling long-range immune activation and support Arc+ VLVs as an antigen-agnostic vaccine for cancer immunotherapy.
- 5 November 2026
- Published by Springer Nature in Nature Nanotechnology
- p. 1-14
Repurposed endogenous virus-like vesicles mediate dendritic cell long-range antigen presentation and T cell activation for enhanced cancer vaccination
Dendritic cells release extracellular vesicles (DEVs) that amplify antigen presentation while incorporating patient-derived, rapidly evolving antigens. By enriching peptide–major histocompatibility complex (MHC) and co-stimulatory ligands orders of magnitude above donor-cell levels, DEVs emerge as potent vesicle-vaccines, although efficacy remains limited by unclear mechanisms. Here we show that dendritic cells repurpose the virus-like retrotransposon-derived Arc gene to generate endogenous virus-like vesicles (VLVs) that predominantly carry peptide–MHC and high-density co-stimulatory ligands, intensifying and extending antigen presentation. Upon antigen exposure, Arc partners with endogenous envelope proteins to assemble VLVs that directly engage T cells and trigger intrinsic adjuvanticity via viral mimicry. DEVs lacking Arc failed to prime antigen-specific T cell responses, whereas Arc overexpression shifted DEVs toward VLVs that trafficked to lymphoid organs, drove rapid CD4-assisted priming and durable CD8-biased memory, suppressed melanoma, and prolonged survival. Our data reveal a viral-mimicry mechanism enabling long-range immune activation and support Arc+ VLVs as an antigen-agnostic vaccine for cancer immunotherapy.
- Open Access
- 5 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (23) , eaea5433
Am80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine
Enteric pathogens are a major contributor to the global disease burden, necessitating vaccines capable of inducing robust gastrointestinal mucosal immunity. Achieving this response is especially challenging with inactivated or subunit vaccines, which lack the ability of live-attenuated formulations to mimic the natural infection process needed to induce strong intestinal mucosal immunity. Specifically, the inactivated polio vaccine (IPV), administered parenterally, elicits strong systemic immunity but fails to induce the mucosal IgA responses required to fully block poliovirus transmission, a critical step toward complete eradication. To address this limitation, we developed a clinically translatable and scalable nanoparticle-based intestinal mucosal adjuvant by encapsulating Am80, a small hydrophobic molecule known to promote intestinal mucosal immunity, within nanoparticles (NPs) designed for lymph node delivery, without requiring antigen modification, encapsulation, or adsorption. Encapsulation in NPs eliminated the need for the use of organic solvents, reduced toxicity, and prevented degradation, while lipid nanoparticles (Am80-LNPs) were engineered for sustained release over 3 to 5 days with high encapsulation efficiency (78 ± 9%). Cy5-labeled Am80-LNPs localized to draining lymph nodes within 6 hours and were retained for up to 72 hours. Coadministration of Am80-LNPs with the licensed IPV-2 in a Wistar rat model significantly boosted IPV-2–specific fecal IgA by 20-fold compared to IPV-2 alone and threefold over free Am80. These findings demonstrate that Am80-LNPs significantly enhance IPV-2–specific mucosal immunity in vivo and suggest their potential as a potent mucosal adjuvant against other enteric pathogens.
- 5 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (23) , eaea5433
Open AccessAm80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine
Enteric pathogens are a major contributor to the global disease burden, necessitating vaccines capable of inducing robust gastrointestinal mucosal immunity. Achieving this response is especially challenging with inactivated or subunit vaccines, which lack the ability of live-attenuated formulations to mimic the natural infection process needed to induce strong intestinal mucosal immunity. Specifically, the inactivated polio vaccine (IPV), administered parenterally, elicits strong systemic immunity but fails to induce the mucosal IgA responses required to fully block poliovirus transmission, a critical step toward complete eradication. To address this limitation, we developed a clinically translatable and scalable nanoparticle-based intestinal mucosal adjuvant by encapsulating Am80, a small hydrophobic molecule known to promote intestinal mucosal immunity, within nanoparticles (NPs) designed for lymph node delivery, without requiring antigen modification, encapsulation, or adsorption. Encapsulation in NPs eliminated the need for the use of organic solvents, reduced toxicity, and prevented degradation, while lipid nanoparticles (Am80-LNPs) were engineered for sustained release over 3 to 5 days with high encapsulation efficiency (78 ± 9%). Cy5-labeled Am80-LNPs localized to draining lymph nodes within 6 hours and were retained for up to 72 hours. Coadministration of Am80-LNPs with the licensed IPV-2 in a Wistar rat model significantly boosted IPV-2–specific fecal IgA by 20-fold compared to IPV-2 alone and threefold over free Am80. These findings demonstrate that Am80-LNPs significantly enhance IPV-2–specific mucosal immunity in vivo and suggest their potential as a potent mucosal adjuvant against other enteric pathogens.
- Open Access
- 20 March 2025
- Published by Springer Nature in Research Square
Repurposed endogenous virus-like vesicles mediate dendritic cell long-range antigen presentation and T-cell activation for enhanced cancer vaccination
Dendritic cells (DCs) can process patient-derived antigens to generate extracellular vesicles (DEVs) vaccines, which can be personalized and rapidly adapted to the evolving antigenic profile in chronic diseases. These DEVs present antigens and stimulate T cell responses, but their clinical efficacy is limited by poorly understood mechanisms. This study reveals how DCs incorporate ancient viral genes to produce endogenous virus-like vesicles (VLVs) that enable long-range T cell communication. Overexpressing a viral capsid protein Arc and a capsid-stabilizer substantially boosted DEVs’ antigen-presentation capabilities and immune responses, whereas Arc-deficient DEVs failed to generate specific immune memory. Proteomic analysis revealed that engineered virus-like vesicles (eraVLVs) enhance antigen presentation on MHC-I, recruit viral proteins for direct T cell interaction, and act as built-in adjuvants to boost broad immune responses. Using a cancer vaccine platform independent of model-specific antigens, we demonstrated robust and broad anti-cancer efficacy, with eraVLVs substantially extending median survival.
- 20 March 2025
- Published by Springer Nature in Research Square
Open AccessRepurposed endogenous virus-like vesicles mediate dendritic cell long-range antigen presentation and T-cell activation for enhanced cancer vaccination
Dendritic cells (DCs) can process patient-derived antigens to generate extracellular vesicles (DEVs) vaccines, which can be personalized and rapidly adapted to the evolving antigenic profile in chronic diseases. These DEVs present antigens and stimulate T cell responses, but their clinical efficacy is limited by poorly understood mechanisms. This study reveals how DCs incorporate ancient viral genes to produce endogenous virus-like vesicles (VLVs) that enable long-range T cell communication. Overexpressing a viral capsid protein Arc and a capsid-stabilizer substantially boosted DEVs’ antigen-presentation capabilities and immune responses, whereas Arc-deficient DEVs failed to generate specific immune memory. Proteomic analysis revealed that engineered virus-like vesicles (eraVLVs) enhance antigen presentation on MHC-I, recruit viral proteins for direct T cell interaction, and act as built-in adjuvants to boost broad immune responses. Using a cancer vaccine platform independent of model-specific antigens, we demonstrated robust and broad anti-cancer efficacy, with eraVLVs substantially extending median survival.